C1q activators constitute a diverse array of chemical entities that are characterized by their ability to enhance the functional activity of the C1q protein, a key component of the classical complement pathway. C1q is primarily recognized for its role in the immune system where it binds to the Fc region of antibodies that are attached to pathogens, triggering a series of immune responses that include the opsonization of pathogens and the initiation of a complement cascade resulting in the formation of a membrane attack complex. Activators of C1q can operate through various mechanisms, with some directly binding to the C1q molecule itself, thereby stabilizing its conformation and enhancing its ability to initiate the complement cascade. Others may work by upregulating the cellular pathways that lead to the expression and stabilization of C1q or its receptor interactions, which are essential for its proper functioning in the immune response. These chemicals, while diverse in structure, share the common feature of promoting the activity of C1q without necessarily increasing its expression.
The biochemical activation mechanisms of C1q activators can be quite intricate. Some activators may influence the configuration of C1q, facilitating its interaction with the C1r2s2 complex, which is a crucial step in the activation of the classical pathway. Other compounds may interact with various regulators of complement activation, such as C1 inhibitor (C1-INH), to sustain a favorable balance that promotes C1q function. By influencing the proteases that cleave and activate downstream components of the complement system, such as C4 and C2, these activators indirectly bolster the function of C1q. Although they do not directly modify the protein structure of C1q, their actions on related molecules and signaling pathways result in a net increase in the functional potential of C1q, thus enhancing its role in the immune system's defense mechanisms. Collectively, these activators work in concert to ensure that C1q can effectively fulfill its role in the recognition and clearance of pathogens, as well as in the removal of apoptotic cells, thereby maintaining homeostasis within the immune system.
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Histone Deacetylase Inhibitors may modify the epigenetic regulation of C1q expression, potentially leading to changes in its activity. | ||||||
MCC950 sodium salt | 256373-96-3 | sc-505904 sc-505904A sc-505904B sc-505904C | 5 mg 10 mg 50 mg 100 mg | $112.00 $194.00 $871.00 $1538.00 | 3 | |
Compounds such as MCC950 can inhibit the NLRP3 inflammasome, which may have downstream effects on complement activation including C1q. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Compounds like BAY 11-7082 that inhibit NF-kB might impact the transcription of complement system genes, including C1q. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
PPARγ Agonists could modulate macrophage function, possibly affecting C1q activity indirectly. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $32.00 $75.00 $118.00 | 14 | |
Sphingosine-1-Phosphate Receptor Modulators could impact lymphocyte egress and function, with potential downstream effects on C1q activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 and other TGF-β pathway inhibitors might influence the expression of complement components, including C1q. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $306.00 | 1 | |
Compounds that inhibit IKK could impact NF-kB signaling and thereby influence C1q expression. |